Company intelligence / Profile preview

Molecular Forecaster

Montréal/Montreal, Quebec, Canadamolecularforecaster.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has secured CAD$1 million to apply and improve its virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease. No clinical results reported as the company provides enabling technology rather than developing its own therapeutics. Their technology has been developed over fifteen years at McGill University. They collaborate with both biotech startups and large pharma companies.

Therapeutic areas: OtherGastroenterologyInfectious Diseases
Modalities: small molecules
Industry: Drug Discovery Services

Partnerships

adMare BioInnovations Center/Accelerate Quebec Program partner

Beyond the preview

Go deeper on Molecular Forecaster.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular Forecaster.

Explore the full profile